Core Insights - Defence Therapeutics Inc. has opened its first U.S. laboratory in the Boston-Cambridge area, marking its initial physical presence in the United States and reinforcing its commitment to advanced research and development in biotechnology [1][2][3] Company Expansion - The new laboratory is located at Cambridge Scientific Labs in Watertown, which will facilitate the development and optimization of the company's proprietary Accum® technology for antibody-drug conjugates (ADCs) [2] - Establishing a presence in the Boston-Cambridge area provides access to top-tier scientific resources and collaboration opportunities within the region's renowned biotech ecosystem [2] Strategic Importance - The CEO of Defence Therapeutics emphasized that this expansion is a significant milestone, positioning the company at the heart of the global biotech community and supporting its mission to advance the Accum® platform for next-generation ADCs [3] - The Cambridge Scientific Labs location will serve as a short-term base while the company evaluates options for a long-term facility in the area [2][3] Company Overview - Defence Therapeutics is a publicly-traded clinical-stage biotechnology company focused on developing next-generation radio-immuno-conjugate and ADC products using its proprietary ACCUM® technology, which enables precision delivery to target cells, enhancing efficacy against cancer [3]

Core Insights - Defence Therapeutics Inc. has appointed Dr. Elias Theodorou as Chief Operating Officer, effective April 2025, to enhance its management team and accelerate development programs [2][3] - Dr. Theodorou brings over 25 years of experience in cancer research and innovative drug delivery systems, which aligns with Defence's mission to advance its proprietary Accum® technology [3][4] - The company has granted Dr. Theodorou 350,000 incentive stock options, with 100,000 vesting immediately and the remainder vesting in one year, exercisable at $1.07 per share for ten years [3] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing radio-immuno-conjugate and antibody-drug conjugate (ADC) products using its proprietary platform [4] - The core technology, Accum®, enables precision delivery of therapeutic agents to target cells, aiming to improve efficacy against cancer and infectious diseases [5]